Group 1 - The company held its fourth meeting of the sixth board of directors on February 9, 2026, to discuss urgent matters, with all 13 directors present [1][2] - The board approved a proposal for issuing shares and paying cash to acquire assets and raise matching funds, confirming compliance with relevant laws and regulations [2][4] - The proposal will be submitted to the shareholders' meeting for further approval [4] Group 2 - The company plans to acquire a 69.8959% stake in Luoyang Fengrui Fluorine Industry Co., Ltd. for a total investment of 150 million yuan, through a combination of share issuance and cash payment [5][6] - The share issuance will involve specific investors, including Wang Zhongxi, Wang Chen, and Shanghai Baidi Investment Management Co., Ltd. [10] - The share issuance price is set at 8.60 yuan per share, which is not less than 80% of the average trading price over the previous 120 trading days [11] Group 3 - The board approved a lock-up period of 12 months for the newly issued shares acquired by the investors [15] - The company will share any undistributed profits before the transaction completion among all shareholders based on their shareholding ratios [17] - Any profits or losses during the transition period will be allocated according to the respective shareholding ratios of the parties involved [19] Group 4 - The cash payment for the transaction will be sourced from raised matching funds and the company's own or self-raised funds [21] - The resolution for the share issuance and cash payment is valid for 12 months from the shareholders' meeting approval [23] - The company will not hold a shareholders' meeting to review the transaction until the relevant audit and evaluation work is completed [80]

Group 1 - The fourth meeting of the board of directors of Zhejiang East Asia Pharmaceutical Co., Ltd. was held on February 6, 2026, with all seven directors present, complying with relevant laws and regulations [2][3]. - The board approved the election of Wang Sheng as a member of the strategic committee, ensuring the normal operation of the committee [3][4]. - The board also approved the revision of the company's seal management system, with unanimous support from all directors [5][4]. Group 2 - The board approved the repurchase and cancellation of 6,000 shares of restricted stock from an incentive object who has left the company, with a repurchase price of 9.47 yuan per share plus applicable interest [6][32]. - The total number of shares to be repurchased represents 0.28% of the total shares granted under the incentive plan and 0.0052% of the company's total share capital [39][32]. - The repurchase will reduce the company's total share capital from 114,726,119 shares to 114,720,119 shares [12][39]. Group 3 - The board approved an increase in the maximum amount for entrusted financial management from 250 million yuan to 300 million yuan, with the same investment period ending on December 8, 2026 [19][20]. - The purpose of this adjustment is to improve the efficiency of the company's idle funds while ensuring daily operational needs and safety [28][20]. - The company will select reputable financial institutions for the entrusted management of funds, focusing on low-risk financial products [20][28].

Core Viewpoint - The announcement details the completion of the repurchase and cancellation of restricted stocks by Harbin Sanlian Pharmaceutical Co., Ltd., involving a total of 3,000 shares, which represents 0.0009% of the company's total share capital before the repurchase [2][11]. Group 1: Repurchase and Cancellation Details - The repurchase price for the restricted stocks was set at 6.48 yuan per share, totaling 19,440 yuan for the repurchase [2][10]. - Following the cancellation, the company's total share capital decreased from 316,357,550 shares to 316,354,550 shares [2][11]. - The repurchase was completed on February 6, 2026, as confirmed by the China Securities Depository and Clearing Corporation [2][10]. Group 2: Background of the Stock Incentive Plan - The 2022 stock incentive plan was approved by the board on July 29, 2022, and involved granting 6,775,183 shares to 175 eligible participants at a price of 6.98 yuan per share [3][5]. - The plan included provisions for repurchasing shares from participants who no longer met the eligibility criteria due to voluntary resignation [9][10]. - The company adjusted the repurchase price from 6.68 yuan to 6.48 yuan per share prior to the cancellation [10]. Group 3: Impact and Future Arrangements - The cancellation of 3,000 shares will not significantly impact the company's financial metrics or daily operations [12]. - The company will proceed with the necessary legal and regulatory procedures for the share cancellation and registration [12].

格隆汇2月6日丨杰普特(688025.SH)公布2026年限制性股票激励计划，本激励计划拟向激励对象授予450 万股限制性股票，约占本激励计划草案公告时公司股本总额的4.73%。其中，首次授予360万股，约占 本激励计划公布时公司股本总额的3.79%，首次授予占本次授予权益总额的80.00%；预留90万股，约占 本激励计划公布时公司股本总额的0.95%，预留部分占本次授予权益总额的20.00%。 ...

本公司及董事会全体成员保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性承担个别及连带责任。 2026年1月27日，山东联科科技股份有限公司（以下简称"公司"）召开第三届董事会第十三次会议，审 议通过了公司《关于〈山东联科科技股份有限公司2026年限制性股票激励计划（草案）〉及其摘要的议 案》等相关议案。具体内容详见公司于2026年1月27日刊载在巨潮资讯网（www.cninfo.com.cn）披露的 相关公告。 根据《上市公司股权激励管理办法》（以下简称"《管理办法》"）、《深圳证券交易所上市公司自律监 管指南第1号一一业务办理》等法律法规和《山东联科科技股份有限公司2026年限制性股票激励计划 （草案）》等相关规定，公司在内部对2026年限制性股票激励计划（以下简称"本激励计划"）授予的激 励对象（以下简称"激励对象"）姓名及职务进行了公示。董事会薪酬与考核委员会结合本次公示情况对 本激励计划的激励对象进行了核查，现说明如下： 一、激励对象名单的公示情况 1、公示内容：2026年限制性股票激励计划拟激励对象的姓名和职务。 2、公示时间：2026年1月27日至20 ...

Core Viewpoint - The company held its first extraordinary general meeting of shareholders in 2026, where several key proposals were approved, including the issuance of overseas bonds and the repurchase of restricted stock. Group 1: Meeting Details - The extraordinary general meeting was held on February 5, 2026, at 3:00 PM, with both on-site and online voting options available [5][7] - A total of 457 shareholders and representatives attended the meeting, representing 200,858,949 voting shares, which is 15.4132% of the total voting shares [10] - The meeting was convened by the company's tenth board of directors and complied with relevant laws and regulations [9][16] Group 2: Proposal Voting Results - The proposal to purchase liability insurance for the company and its directors was approved with 199,029,953 votes in favor, accounting for 99.0894% of the votes [11] - The proposal to repurchase and cancel part of the restricted stock from the 2025 incentive plan was approved with 199,532,124 votes in favor, representing 99.3394% [12] - The proposal to change the registered capital and amend the company's articles of association was approved with 199,560,357 votes in favor, which is 99.3535% [13] - The proposal for the company to issue overseas bonds was approved with 199,531,219 votes in favor, accounting for 99.3390% [14][15] Group 3: Stock Repurchase and Capital Reduction - The company decided to repurchase and cancel 50,000 shares of restricted stock at a price of 4.30 yuan per share due to the termination of one incentive recipient's employment [17][18] - Following the repurchase, the registered capital will decrease from 1,303,158,541 yuan to 1,303,108,541 yuan [18] - The company will notify creditors regarding the capital reduction, allowing them to claim debts within specified timeframes [19][20]

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688111 证券简称：金山办公 公告编号：2026-001 北京金山办公软件股份有限公司 关于2022年、2023年、2024年限制性股票激励计划部分限制性股票归属结果暨股份上市的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 重要内容提示： ● 本次股票上市类型为股权激励股份；股票认购方式为网下，上市股数为192,828股。 本次股票上市流通总数为192,828股，占归属前公司总股本的比例为0.0416%。其中，2022年限制性股票 激励计划首次授予部分第二类激励对象第三个归属期归属2,210股，2022年限制性股票激励计划预留授 予部分第三个归属期归属62,050股，2023年限制性股票激励计划预留授予部分第二个归属期归属64,548 股，2024年限制性股票激励计划预留授予部分第一个归属期归属64,020股。 ● 本次股票上市流通日期：2026年2月12日。 根据中国证监会、上海证券交易所、中国证券登记结算有限责任公司上海分公司有关业务规则的规定， ...

2、公司于2026年1月27日至2026年2月5日在公司内部公示栏对本次拟激励对象的姓名和职务进行了公 示，公示期共计10天，公司员工可向公司董事会薪酬与考核委员会提出意见。截至公示期满，公司董事 会薪酬与考核委员会未收到任何组织或个人对本次拟激励对象提出的异议。 3、薪酬与考核委员会对激励对象的核查方式 登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：688127 证券简称：蓝特光学 公告编号：2026-015 浙江蓝特光学股份有限公司董事会薪酬与考核委员会关于公司2026年限制性股票 激励计划激励对象名单的公示情况说明及核查意见 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述或者重大遗漏，并对其内容 的真实性、准确性和完整性依法承担法律责任。 浙江蓝特光学股份有限公司（以下简称"公司"）于2026年1月26日召开第五届董事会第二十六次会议， 审议通过了《关于公司〈2026年限制性股票激励计划（草案）〉及其摘要的议案》等议案。根据《上市 公司股权激励管理办法》（以下简称"《管理办法》"）《上海证券交易所科创板股票上市规则》《科创 板上市公司自律监管指南第4号一一股权激励信息披 ...

登录新浪财经APP 搜索【信披】查看更多考评等级 证券代码：001255 证券简称：博菲电气 公告编号：2026-016 浙江博菲电气股份有限公司 关于2025年限制性股票激励计划预留授予 限制性股票授予登记完成的公告（新增股份） 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误导性陈述或重大遗 漏。 重要内容提示： 1、上市日（新增股份）：2026年2月9日 2、登记数量（新增股份）：67.20万股 3、授予价格：12.98元/股 4、授予登记人数（新增股份）：4人 5、授予的股票来源（新增股份）：公司向激励对象定向发行的本公司人民币A股普通股 （四）2025年5月29日，公司召开第三届董事会第十五次会议、第三届监事会第十二次会议，审议通过 了《关于调整公司2025年限制性股票激励计划相关事项的议案》《关于向公司2025年限制性股票激励计 划激励对象首次授予限制性股票的议案》。公司监事会对激励对象名单进行了核查并发表了意见。 （五）2025年11月28日，公司召开第三届董事会第二十二次会议、第三届监事会第十七次会议，审议通 过了《关于回购注销2025年限制性股票激励计划部分限制性股 ...

Core Viewpoint - The company has completed the registration of restricted stock vesting, leading to an adjustment in the conversion price of its convertible bonds, which will affect the trading of its securities [2][6]. Group 1: Stock Vesting and Price Adjustment - The company completed the registration of 203,310 shares from the fourth vesting period of its 2020 restricted stock incentive plan on February 4, 2026, increasing its total share capital from 460,238,329 shares to 460,441,639 shares [2][24]. - The conversion price of the "Raytron Convertible Bonds" has been adjusted from 39.13 CNY per share to 39.12 CNY per share, effective from February 9, 2026 [6][8]. - The adjustment in the conversion price is based on the issuance of new shares and follows specific formulas outlined in the company's bond issuance prospectus [4][8]. Group 2: Financial Impact and Shareholder Information - The newly issued shares represent approximately 0.04% of the total share capital before the vesting, which is not expected to have a significant impact on the company's recent financial performance [26]. - The company reported a net profit attributable to shareholders of approximately 706.78 million CNY for the first nine months of 2025, with an expected dilution in earnings per share due to the increase in total shares [26]. - The shares from the incentive plan will be listed for trading on February 10, 2026, and there are specific transfer restrictions for shares held by directors and senior management [13][24].